中成药治疗非酒精性脂肪性肝病的网状Meta分析
该网状Meta分析纳入39项RCT、13种中成药、4049例非酒精性脂肪性肝病患者,比较不同中成药疗效。结果显示芝柏泰胶囊在提高临床有效率方面可能最优,六味五灵片降低ALT和AST最佳,甘丹舒康胶囊降低GGT最佳,强肝胶囊降低TG最佳,当飞利肝宁胶囊降低TC最佳,纳入研究无严重不良反应。
要点
- 芝柏泰胶囊可能为提高NAFLD临床有效率的最佳中成药选择。
- 六味五灵片降低血清ALT和AST效果最佳。
- 甘丹舒康胶囊降低GGT、强肝胶囊降低TG、当飞利肝宁胶囊降低TC各具优势。
核心结论
- 对于该网状Meta分析中的非酒精性脂肪性肝病患者,芝柏泰胶囊、六味五灵片、甘丹舒康胶囊、强肝胶囊、当飞利肝宁胶囊可能值得关注。
- 由于存在不明确的偏倚风险,需要设计更好的双盲、多中心、大样本随机对照试验来解决盲法、选择性报告和分配隐藏的问题。
研究设计与样本
- 研究为网状Meta分析,检索PubMed、Embase、Cochrane Library、Web of Science、中国知网、万方数据库、中国科技期刊数据库和中国生物医学文献数据库,检索时间从建库至2022年7月。
- 共纳入39项随机对照试验,涉及13种中成药,包括4049例患者,其中42例脱落。
- 使用Review Manager 5.4和Cochrane协作网系统评价员手册评估偏倚风险,采用基于频率理论的STATA 16.0进行网状Meta分析。
主要发现
- 在提高临床有效率方面,芝柏泰胶囊最可能是非酒精性脂肪性肝病的最佳中成药选择。
- 六味五灵片在降低血清ALT和AST方面效果最佳。
- 甘丹舒康胶囊在降低血清GGT方面效果最佳。
- 强肝胶囊在降低血清TG方面效果最佳。
- 当飞利肝宁胶囊在降低血清TC方面效果最佳。
临床怎么用
- 临床可结合患者具体指标异常(如ALT/AST升高、GGT升高、TG或TC升高)参考相应中成药的可能优势选择用药。
- 应用上述中成药时需关注原始研究偏倚风险不明确的问题,并结合临床实际个体化决策。
局限性
- 纳入研究存在不明确的偏倚风险,涉及盲法、选择性报告和分配隐藏等问题。
- 需要更多设计良好的双盲、多中心、大样本随机对照试验进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: The incidence of Non-alcoholic fatty liver disease (NAFLD) is increasing year by year. Researches showed that Chinese patent medicines (CPMs) had achieved good efficacy in the treatment of Non-alcoholic fatty liver disease. However, the debate on optimum Chinese patent medicine (CPM) persists. Therefore, we conducted a network meta-analysis to objectively compare the efficacy of different Chinese patent medicines in the treatment of Non-alcoholic fatty liver disease. Methods: PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure, Wanfang Database, China Science and Technology Journal Database, and Chinese Biomedical Literature Database were used as databases for RCT researches retrieval. The retrieval time was from establishment of the database to July 2022. After effective data was extracted, Review Manager 5.4 and Cochrane Collaboration System Evaluator's Manual were used to assess bias risk. STATA 16.0 based on frequency theory was used for the network meta-analysis. Results: Totally 39 studies were included, involving 13 Chinese patent medicines, including 4049 patients, of which 42 patients were lost. In terms of improving clinical efficiency rate, Zhibitai capsule was most likely the best choice of Chinese patent medicine for Non-alcoholic fatty liver disease. Liuwei Wuling tablet had the best effect in reducing serum ALT and AST; Gandan Shukang capsule had the best effect in reducing serum GGT; Qianggan capsule had the best effect in reducing serum TG; Dangfei Liganning capsule had the best effect in reducing serum TC. None of the included studies had serious adverse reactions. Conclusion: For patients with Non-alcoholic fatty liver disease in this NMA, Zhibitai capsule, Liuwei Wuling tablet, Gandan Shukang capsule, Qianggan capsule, Dangfei Liganning capsule might be noteworthy. Due to the uclear risk bias, better designed double-blind, multi center and large sample RCTs are needed which resolve the problems of blinding, selective reporting and allocation concealment. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42022341240.
引用
- Zhang L, Liu S, Gu Y, et al. Comparative efficacy of Chinese patent medicines for non-alcoholic fatty liver disease: A network meta-analysis. Front Pharmacol. 2023. PMID: 36686656. doi:10.3389/fphar.2022.1077180
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。